Sana Biotechnology (NASDAQ:SANA) Rating Increased to Sell at Wall Street Zen

Key Points

• Wall Street Zen upgraded Sana Biotechnology from "strong sell" to "sell", but the stock still carries a generally mixed analyst view.
• Analyst sentiment is mostly constructive overall: six analysts rate the stock a Buy, one a Hold, and one a Sell, with an average target price of $8.20. Recent reports also included target-price changes from Wedbush, HC Wainwright, and others.
• Sana Biotechnology is trading at $3.51, below its 200-day moving average of $4.04, and the company recently reported a quarterly loss of ($0.16) EPS, missing expectations by $0.03.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) was upgraded by Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued to investors on Saturday.

Other analysts have also issued research reports about the stock. Wedbush lifted their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Tuesday, April 14th. Zacks Research lowered shares of Sana Biotechnology from a "strong-buy" rating to a "hold" rating in a report on Tuesday, March 3rd. Weiss Ratings lowered shares of Sana Biotechnology from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, May 1st. Morgan Stanley reissued an "overweight" rating and issued a $12.00 price target on shares of Sana Biotechnology in a report on Friday, March 13th. Finally, HC Wainwright decreased their price target on shares of Sana Biotechnology from $9.00 to $7.00 and set a "buy" rating for the company in a report on Wednesday, March 4th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sana Biotechnology has an average rating of "Moderate Buy" and an average target price of $8.20.

Sana Biotechnology Stock Performance

SANA opened at $3.51 on Friday. The company has a fifty day moving average price of $3.36 and a two-hundred day moving average price of $4.04. Sana Biotechnology has a 52 week low of $1.60 and a 52 week high of $6.55. The firm has a market capitalization of $947.67 million, a PE ratio of -3.62 and a beta of 2.17.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Tuesday, March 3rd. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.03). Equities analysts forecast that Sana Biotechnology will post -0.59 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Sana Biotechnology by 4.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 52,872 shares of the company's stock valued at $188,000 after buying an additional 2,023 shares during the period. Xponance LLC boosted its stake in Sana Biotechnology by 25.6% in the 4th quarter. Xponance LLC now owns 13,068 shares of the company's stock worth $53,000 after purchasing an additional 2,662 shares during the period. Creative Planning boosted its stake in Sana Biotechnology by 5.3% in the 3rd quarter. Creative Planning now owns 54,177 shares of the company's stock worth $192,000 after purchasing an additional 2,719 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Sana Biotechnology by 29.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,944 shares of the company's stock worth $53,000 after purchasing an additional 2,943 shares during the period. Finally, Savant Capital LLC boosted its stake in Sana Biotechnology by 5.6% in the 3rd quarter. Savant Capital LLC now owns 66,414 shares of the company's stock worth $236,000 after purchasing an additional 3,500 shares during the period. Institutional investors and hedge funds own 88.23% of the company's stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.